Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.92 |
| ▸ | PDE6D | O43924 | 5/20 | 0.81 |
| ▸ | PDE6A | P16499 | 5/20 | 0.81 |
| ▸ | PDE6G | P18545 | 5/20 | 0.81 |
| ▸ | PDE6B | P35913 | 5/20 | 0.81 |
| ▸ | PDE6C | P51160 | 5/20 | 0.81 |
| ▸ | PDE6H | Q13956 | 5/20 | 0.81 |
| ▸ | PDE11A | Q9HCR9 | 7/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | ACHE | P22303 | 1/20 | 0.78 |
| ▸ | PDE4A | P27815 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.78 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.78 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1327321 | 1.00 | PDE5A (0.92) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL1327324 | 1.00 | PDE5A (0.92) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6782140 | 0.97 | PDE5A (0.98) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6782131 | 0.97 | PDE5A (0.98) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6782137 | 0.97 | PDE5A (0.98) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL1327741 | 0.97 | PDE5A (0.98) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7443215 | 0.96 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7689513 | 0.96 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7689516 | 0.96 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL17390222 | 0.95 | PDE5A (0.86) | PDE5APDE6DPDE6APDE6GPDE6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | claimed |
| US-6140329-A | FOR TREATING A MALE ANIMAL FOR ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-10-31 | — | — | US | claimed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | claimed |
| US-9943398-B2 | Increasing survival of free tissue grafts and flaps using phosphodiesterase type 5 (PDE5) inhibitors | NEW YORK UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-20140018936-A1 | INCREASING SURVIVAL OF FREE TISSUE GRAFTS AND FLAPS USING PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS | NEW YORK UNIVERSITY (US) | 2014-01-16 | — | — | US | disclosed |
| US-8058305-B2 | Pyrrolidine derivatives as prostaglandin modulators | MERCK SERONO SA (CH) | 2011-11-15 | — | — | US | disclosed |
| EP-1458679-B1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2009-11-26 | — | — | US | disclosed |
| EP-1331950-B1 | EX VIVO METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | UNIV JOHNS HOPKINS (US) | 2009-10-14 | — | — | EP | disclosed |
| US-7335680-B2 | Pyrrolidine derivatives as prostaglandin modulators | LABORATOIRES SERONO SA (CH) | 2008-02-26 | — | — | US | disclosed |
| US-6992070-B2 | Methods and compositions for nucleic acid delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | ICOS CORPORATION | 2002-08-29 | — | — | US | disclosed |
| WO-2001078781-A9 | METHODS FOR PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS | UNIV JOHNS HOPKINS (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020094326-A1 | Methods and compositions for nucleic acid delivery | JOHNS HOPKINS UNIVERSITY | 2002-07-18 | — | — | US | disclosed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | disclosed |
| US-6140329-A | FOR TREATING A MALE ANIMAL FOR ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | disclosed |
| EP-0740668-B1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | ICOS CORP (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0839040-A1 | USE OF CGMP-PHOSPHODIESTERASE INHIBITORS TO TREAT IMPOTENCE | ICOS CORPORATION (US) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997003675-A1 | USE OF CGMP-PHOSPHODIESTERASE INHIBITORS TO TREAT IMPOTENCE | ICOS CORPORATION (US) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | PGF, PTGIS, PDE5A | PDE5A 3/4885PDE6D 187/4885PDE6A 74/4885 |
| US-20020094326-A1 | Methods and compositions for nucleic acid delivery | TNNC1, TNNI3, TNNT2 | PDE5A 2130/4885PDE6D 1389/4885PDE6A 1004/4885 |
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | PDE3A, PDE3B, PDE2A | PDE5A 5/4885PDE6D 7/4885PDE6A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.